跳至主要内容
临床试验/NL-OMON39097
NL-OMON39097已完成不适用

Pediatric microdosing: elucidating age-related changes in oral absorption - PedMic

Erasmus MC, Universitair Medisch Centrum Rotterdam0 个研究点目标入组 32 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
32

研究概览

简要总结

Trial ended prematurely

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 11(—)

入选标准

  • Age 0 to 6 years inclusive
  • At least 32 weeks of post conceptual age
  • Intravenous or intra-arterial access for blood sampling in place
  • Receiving paracetamol IV
  • Parental informed consent

排除标准

  • Anticipated death in 48 hours
  • No informed consent
  • ECMO treatment
  • Circulatory failure:
  • - receiving more than 1 vasopressor or
  • - increase of vasopressor drug dose in the last 6 hours
  • Renal disorders
  • - In need of renal dialysis
  • - Estimated risk for kidney injury or failure at least 'risk for renal dysfunction' according to pRIFLE criteria. Which means an estimated creatinine clearance decreased by 25% or more, or urine output of <0.5mL/kg per hour for 8 hours.
  • Hepatic failure:
  • - >2SD in age appropriate liver enzymes measurement (ASAT and ALAT)
  • Gastrointestinal disorders
  • - Ileus, diarrhea, short bowel disease, underlying inflammatory bowel disease, pancreatic insufficency, (e.g. cystic fibrosis), celiac disease
  • Use of co-medication known to affect paracetamol metabolism (according to the Farmacotherapeutische Kompas, www.fk.cvz.nl)

研究者

相似试验